Merck and Japan-based Daiichi Sankyo announced on May 29, 2025, that they have withdrawn the U.S. application for an experimental lung cancer treatment. The drug belongs to a lucrative class of cancer therapies known as 'guided missiles' or antibody-drug conjugates (ADCs).
The withdrawal represents a regulatory setback for this promising oncology asset. While the specific reasons for the withdrawal were not detailed in the announcement, it indicates a pause or re-evaluation of the drug's path to market in the U.S.
This development impacts Merck's efforts to diversify its oncology pipeline and bring innovative treatments to patients. The companies will likely reassess their strategy for this particular lung cancer treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.